Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus HALCINONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus HALCINONIDE.
COR-OTICIN vs HALCINONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Halcinonide is a corticosteroid that binds to glucocorticoid receptors, leading to increased synthesis of lipocortin (annexin-1), which inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
1-2 drops in each affected ear twice daily for 7 days.
Apply thin film topically to affected area 2 to 3 times daily.
None Documented
None Documented
Clinical Note
moderateHalcinonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Halcinonide is combined with Gatifloxacin."
Clinical Note
moderateHalcinonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Halcinonide is combined with Rosoxacin."
Clinical Note
moderateHalcinonide + Levofloxacin
"The risk or severity of adverse effects can be increased when Halcinonide is combined with Levofloxacin."
Clinical Note
moderateHalcinonide + Trovafloxacin
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal half-life: 4-6 hours; supports twice-daily topical dosing.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Renal: ~50% as metabolites; biliary/fecal: ~40% as metabolites and unchanged drug.
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid
"The risk or severity of adverse effects can be increased when Halcinonide is combined with Trovafloxacin."